Skip to main content
RGEN
NASDAQ Life Sciences

Repligen Rebuts ISS and Glass Lewis Recommendations Against Key Directors Amidst Governance Concerns

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Negative
Importance info
8
Price
$118.9
Mkt Cap
$6.671B
52W Low
$109.5
52W High
$175.77
Market data snapshot near publication time

summarizeSummary

Repligen Corporation filed additional proxy materials to rebut negative recommendations from Institutional Shareholder Services (ISS) and Glass Lewis against the re-election of certain directors, including Audit Committee members and the Board Chair, citing material weaknesses in internal controls, delayed filings, and board diversity disclosures.


check_boxKey Events

  • Proxy Advisors Recommend Against Directors

    Institutional Shareholder Services (ISS) recommended against the re-election of Audit Committee members Glenn P. Muir, Karen A. Dawes, and Carrie Eglinton Manner. Glass Lewis recommended against Dr. Martin D. Madaus, Ph.D., Board Chair and Chair of the Nominating and Corporate Governance Committee.

  • Reasons for Negative Recommendations

    ISS cited material weaknesses in internal control over financial reporting and non-timely filing of reports. Glass Lewis cited incomplete disclosure of board-level diversity metrics.

  • Company Rebuts Allegations

    Repligen strongly disagrees with both recommendations, detailing remediation of two material weaknesses, progress on remaining weaknesses, and significant organizational investments to enhance its control environment. The company also provided additional board diversity disclosures.

  • Engagement of Proxy Solicitor

    The company engaged Okapi Partners, a proxy solicitation firm, for a fee of approximately $35,000 plus expenses, to assist in soliciting proxies for the upcoming Annual Meeting.


auto_awesomeAnalysis

This DEFA14A filing is highly important as it signals a significant challenge to Repligen's corporate governance ahead of its Annual Meeting. The company is actively defending its Audit Committee members against ISS's recommendation, which stems from previously disclosed material weaknesses in internal controls and past filing delays. While the company highlights the remediation of two material weaknesses and significant investments in its control environment, the ongoing nature of some weaknesses and the need for such a detailed defense underscore the seriousness of these governance concerns. Similarly, the rebuttal against Glass Lewis regarding board diversity, while less impactful than financial control issues, adds to the scrutiny on the board. Shareholders will need to carefully consider these arguments when voting on director re-elections, as the outcome could impact the company's oversight and financial reporting integrity. The engagement of a proxy solicitor indicates the company is taking these recommendations seriously and actively campaigning for shareholder support.

At the time of this filing, RGEN was trading at $118.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $109.50 to $175.77. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed RGEN - Latest Insights

RGEN
Apr 27, 2026, 4:03 PM EDT
Filing Type: DEFA14A
Importance Score:
8
RGEN
Apr 02, 2026, 4:13 PM EDT
Filing Type: DEF 14A
Importance Score:
7
RGEN
Feb 26, 2026, 4:03 PM EST
Filing Type: 10-K
Importance Score:
8
RGEN
Feb 24, 2026, 7:33 AM EST
Filing Type: 8-K
Importance Score:
7